Carbamazepine Biosensor Development for Epilepsy Patient Screening

Annu Int Conf IEEE Eng Med Biol Soc. 2021 Nov:2021:1531-1534. doi: 10.1109/EMBC46164.2021.9629901.

Abstract

The San Carlos population in Chile is an example of an underserved community due to lack of timely access to regular controls and laboratory results. One particular challenge is the adherence to treatment of Epilepsy patients. In this work, we present the design and proof-of-concept of a Point of Care Device (POCD) to measure carbamazepine levels in saliva to screen for correct dose prescription among epilepsy patients. We present the Screen Printed Electrode design and activating circuit and preliminary results to verify feasibility of the biosensor. Future steps include the fabrication of the device itself and validation with the target population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biosensing Techniques*
  • Carbamazepine / therapeutic use
  • Electrodes
  • Epilepsy* / diagnosis
  • Epilepsy* / drug therapy
  • Humans
  • Saliva

Substances

  • Carbamazepine